Inventor · disambiguated record
Paul R. Hinton
Also filed as: HINTON PAUL · HINTON PAUL R · HINTON PAUL ROBERT
22 granted patents·23 pending applications·1,326 citations·filing 1995–2023
97Inventor score
Top patents by PatentIndex Score
45 records- 0199US7217797B2Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisPDL BIOPHARMA INC·Filed 2003·Granted May 15, 2007·298 cites·50 claims
- 0298US7217798B2Alteration of Fc-fusion protein serum half-lives by mutagenesisPDL BIOPHARMA INC·Filed 2004·Granted May 15, 2007·134 cites·15 claims
- 0397US7915388B2Interleukin-13 binding proteinsABBOTT LAB·Filed 2007·Granted Mar 29, 2011·96 cites·41 claims
- 0497US7361740B2Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisPDL BIOPHARMA INC·Filed 2004·Granted Apr 22, 2008·92 cites·16 claims
- 0596US7732570B2Alteration of Fc-fusion protein serum half-lives by mutagenesisFACET BIOTECH CORP·Filed 2007·Granted Jun 8, 2010·26 cites·4 claims
- 0696US7365168B2Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisPDL BIOPHARMA INC·Filed 2005·Granted Apr 29, 2008·38 cites·8 claims
- 0795US7700739B2IL-12/p40 binding proteinsABBOTT LAB·Filed 2006·Granted Apr 20, 2010·57 cites·117 claims
- 0895US7034121B2Antibodies against CTLA4GENETICS INSTITUE LLC·Filed 2001·Granted Apr 25, 2006·200 cites·2 claims
- 0994US6218149B1Antibodies having modified carbohydrate content and methods of preparation and useTRUSTEES OF COLUMBUS UNIVERSIT·Filed 1995·Granted Apr 17, 2001·194 cites·12 claims
- 1093US7320790B2Humanized antibodiesLILLY CO ELI·Filed 2002·Granted Jan 22, 2008·55 cites·17 claims
- 1193US7122185B2Anti-CCR5 antibodyPDL BIOPHARMA INC·Filed 2003·Granted Oct 17, 2006·50 cites·75 claims
- 1292US9592293B2Interleukin-13 binding proteinsABBVIE INC·Filed 2013·Granted Mar 14, 2017·18 cites·13 claims
- 1392US7666419B2Anti-CCR5 antibodyPROGENICS PHARM INC·Filed 2006·Granted Feb 23, 2010·14 cites·36 claims
- 1489US8629257B2IL-12/p40 binding proteinsLACY SUSAN E·Filed 2010·Granted Jan 14, 2014·18 cites·33 claims
- 1587US11344621B2Interleukin-13 binding proteinsABBVIE INC·Filed 2018·Granted May 31, 2022·2 cites·35 claims
- 1686US10086076B2Interleukin-13 binding proteinsABBVIE INC·Filed 2017·Granted Oct 2, 2018·4 cites·11 claims
- 1784US7442777B2Cytotoxicity mediation of cells evidencing surface expression of CD63ARIUS RES INC·Filed 2006·Granted Oct 28, 2008·6 cites·5 claims
- 1884US7223393B2Amphiregulin antibodies and their use to treat cancer and psoriasisPDL BIOPHARMA INC·Filed 2004·Granted May 29, 2007·16 cites·6 claims
- 1983US7851600B2Anti-CCR5 antibodyPROGENICS PHARM INC·Filed 2006·Granted Dec 14, 2010·3 cites·27 claims
- 2078US8604177B2Interleukin-13 binding proteinsWU CHENGBIN·Filed 2011·Granted Dec 10, 2013·3 cites·30 claims
- 2175US8624007B2Alteration of Fc-fusion protein serum half-lives by mutagenesisHINTON PAUL R·Filed 2010·Granted Jan 7, 2014·2 cites·7 claims
- 2269US2022403009A1Multimeric coronavirus binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2364US2023058162A1Multimeric coronavirus binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2463US2025051473A1Anti-cd38 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2563US2020308290A1Anti-cd25 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2660US2024076392A1Anti-cd123 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2760US2006165706A1Antibodies against CTLA4 and uses thereforGENETICS INST LLC·Filed 2005·Application pending·0 cites
- 2859US10150814B2Fc variants with improved complement activationABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Dec 11, 2018·0 cites·14 claims
- 2956US2022267415A1Multimeric sars-cov-2 binding molecules and uses thereofUNIV TEXAS·Filed 2022·Application pending·0 cites
- 3056US2014178332A1IL-12/p40 BINDING PROTEINSABBVIE INC·Filed 2014·Application pending·0 cites
- 3156US2015010539A1Anti-cd25 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3255US2009155262A1Cytotoxicity mediation of cells evidencing surface expression of CD63YOUNG DAVID S F·Filed 2008·Application pending·0 cites
- 3355US2008226632A1Amphiregulin antibodies and their use to treat cancer and psoriasisPDL BIOPHARMA INC·Filed 2007·Application pending·0 cites
- 3454US2022372142A1Multimeric antibodies with enhanced selectivity for cells with high target densityIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3553US2023073926A1Highly sialylated multimeric binding moleculesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3651US2017233481A1Anti-cd25 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3751US2002028486A1Antibodies having modified carbohydrate content and methods of preparation and useUNIV COLUMBIA·Filed 2001·Application pending·0 cites
- 3850US2021380701A1MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULESIGM BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 3950US2014377253A1Fc variantsABBVIE BIOTHERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4049US2009175847A1Humanized antibodies to ab (20-42) globulomer and uses thereofABBOTT LAB·Filed 2008·Application pending·0 cites
- 4149US2009232801A1Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses ThereofABBOTT LAB·Filed 2008·Application pending·0 cites
- 4248US2018251565A1Fc variantsABBVIE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4348US2014186377A1Prostaglandin e2 binding proteins and uses thereofABBVIE INC·Filed 2013·Application pending·0 cites
- 4445US2007276289A1Self-contained specimen collection and testing deviceHINTON PAUL·Filed 2006·Application pending·0 cites
- 4542US2004116675A1Silenced anti-cd28 antibodies and use thereofFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Paul R. Hinton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →